



ALEMBIC PHARMACEUTICALS LIMITED
 Regd. Office: Alembic Road, Vadodara 390 003
 CIN:L24230GJ2010PLC061123
 Ph #:0265 2280550 Fax #: 2280880
 Email : apl.investors@alembic.co.in Website: www.alembic-india.com

**AUDITED FINANCIAL RESULTS
 FOR THE YEAR ENDED 31ST MARCH, 2015**

Rs. In Lacs

	Particulars	CONSOLIDATED				
		Quarter Ended			Year Ended	
		March-15	December-14	March-14	March-15	March-14
		(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
PART- I						
1	(a) Net Sales / Income from Operations					
	Domestic	27,530	29,281	24,536	117,394	104,106
	Exports	23,265	22,209	21,986	89,379	82,735
	Total	50,795	51,490	46,522	206,773	186,841
	Less : Excise Duty	612	395	189	1,505	771
	Net Sales / Income from Operations	50,183	51,095	46,333	205,268	186,070
	(b) Other Operating Income	115	83	70	344	251
	Total Income from Operations	50,298	51,178	46,403	205,612	186,321
2	Expenses					
	(a) Decrease/(increase) in stock in trade and work in progress	447	(1,399)	407	(7,289)	(4,065)
	(b) Consumption of Raw Materials & Packing Materials	11,459	12,361	13,088	54,049	55,593
	(c) Purchase of traded goods	5,449	6,471	4,128	24,692	19,807
	(d) Employees' Cost	7,522	7,916	6,715	30,676	24,700
	(e) Marketing Expense	3,945	5,615	3,088	21,766	16,618
	(f) Research and Development Expense	3,049	3,051	3,120	12,162	11,643
	(g) Excise Duty	95	427	62	796	425
	(h) Other Expenditure	8,466	6,488	6,666	28,153	25,829
	Total Expenses	40,432	40,930	37,274	165,005	150,550
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	9,866	10,248	9,129	40,607	35,771
4	Other Income	185	13	277	230	319
5	Profit from Ordinary Activities before Interest, Depreciation, & Exceptional Items	10,051	10,261	9,406	40,837	36,090
6	Depreciation	1,096	1,190	1,099	4,441	4,049
7	Interest (Net)	36	(18)	229	178	981
8	CSR Expense	71	91	-	310	-
9	Net Profit from Ordinary Activities before Tax	8,848	8,998	8,078	35,908	31,060
10	Tax Expense					
	Less : Provision for Current Tax	1,831	1,933	1,801	7,635	6,847
	Add : MAT Credit Entitlement	739	-	-	739	-
	Less : Provision for Deferred Tax Liability	739	-	148	739	663
11	Net Profit from Ordinary Activities after Tax	7,017	7,065	6,129	28,273	23,550
12	Share of Profit of Associates	16	1	-	20	-
13	Net Profit after Tax and share of profit of associates	7,033	7,066	6,129	28,293	23,550
14	Paid up Equity Share Capital (Face value of share ` 2/-)	3,770	3,770	3,770	3,770	3,770
15	Reserves excluding Revaluation Reserve	-	-	-	84,694	63,787
16	Basic & Diluted EPS (Not Annualised)	3.73	3.75	3.25	15.01	12.49
PART- II						
A	Particulars of Shareholding					
1	Public Shareholding					
	- Number of Shares	48777294	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding					
	- Fully Non - Encumbered					
	- Number of Shares	139738620	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter Ended on 31st MARCH, 2015				
	Pending at the beginning of the quarter	NIL				
	Received during the quarter	NIL				
	Disposed of during the quarter	NIL				
	Remaining unresolved at the end of the quarter	NIL				


ALEMBIC PHARMACEUTICALS LIMITED

Regd. Office: Alembic Road, Vadodara 390 003

CIN:L24230GJ2010PLC061123

Ph #:0265 2280550 Fax #: 2280880

Email : apl.investors@alembic.co.in Website: www.alembic-india.com

**AUDITED FINANCIAL RESULTS
FOR THE YEAR ENDED 31ST MARCH, 2015**

Rs. in lacs

	Particulars	STANDALONE				
		Quarter Ended			Year Ended	
		March-15 (Audited)	December-14 (Reviewed)	March-14 (Audited)	March-15 (Audited)	March-14 (Audited)
PART- I						
1	(a) Net Sales / Income from Operations					
	Domestic	27,530	29,281	24,536	117,394	104,106
	Exports	22,361	21,233	21,092	85,681	80,793
	Total	49,891	50,514	45,628	203,075	184,899
	Less : Excise Duty	612	395	189	1,505	771
	Net Sales / Income from Operations	49,279	50,119	45,439	201,570	184,128
	(b) Other Operating Income	101	83	70	330	251
	Total Income from Operations	49,380	50,202	45,509	201,900	184,379
2	Expenses					
	(a) Decrease/(increase) in stock in trade and work in progress	447	(1,399)	407	(7,289)	(4,065)
	(b) Consumption of Raw Materials & Packing Materials	11,459	12,361	13,088	54,049	55,593
	(c) Purchase of traded goods	5,495	6,395	4,128	24,663	19,807
	(d) Employees' Cost	7,245	7,658	6,677	29,657	24,446
	(e) Marketing Expense	3,633	5,272	2,934	20,318	16,075
	(f) Research and Development Expense	2,820	2,559	2,593	10,903	10,510
	(g) Excise Duty	95	427	62	796	425
	(h) Other Expenditure	8,474	6,371	6,955	27,712	25,686
	Total Expenses	39,668	39,644	36,844	160,809	148,477
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	9,712	10,558	8,665	41,091	35,902
4	Other Income	12	13	277	57	319
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	9,724	10,571	8,942	41,148	36,221
6	Depreciation	1,096	1,190	1,099	4,441	4,049
7	Interest (Net)	5	(42)	229	111	981
8	CSR Expense	71	91	-	310	-
9	Net Profit from Ordinary Activities before Tax	8,552	9,332	7,614	36,286	31,191
10	Tax Expense					
	Less : Provision for Current Tax	1,843	1,933	1,752	7,625	6,700
	Add : MAT Credit Entitlement	739	-	-	739	-
	Less : Provision for Deferred Tax Liability	739	-	148	739	663
11	Net Profit from Ordinary Activities after Tax	6,709	7,399	5,714	28,661	23,828
12	Paid up Equity Share Capital (Face value of share Rs. 2/-)	3,770	3,770	3,770	3,770	3,770
13	Reserves excluding Revaluation Reserve	-	-	-	79,586	59,199
14	Basic & Diluted EPS (Not Annualised)	3.56	3.92	3.03	15.20	12.64
PART- II						
A	Particulars of Shareholding					
1	Public Shareholding					
	- Number of Shares	48777294	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding					
	- Fully Non - Encumbered					
	- Number of Shares	139738620	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter Ended on 31st March, 2015				
	Pending at the beginning of the quarter	NIL				
	Received during the quarter	NIL				
	Disposed of during the quarter	NIL				
	Remaining unresolved at the end of the quarter	NIL				

Notes :

- 1 The above results, have been duly audited by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors.
- 2 The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com.

The key information on the standalone financial results are as under:

Particulars	Quarter Ended			Year Ended	
	Mar/15	Dec/14	Mar/14	Mar/15	Mar/14
	(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
Net Sales / Income from Operations	49,380	50,202	45,509	201,900	184,379
Profit Before Tax	8,552	9,332	7,614	36,286	31,191
Profit After Tax	6,709	7,399	5,714	28,661	23,828

- 3 The Board has recommended dividend of Equity Shares at Rs 3.50 per share i.e 175% for the year ended on 31.03.2015 (P Y Rs. 3.00 per share)
- 4 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 5 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 27th April, 2015

Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com